U.S. License Holder:
Hospira Inc.
Date of License:
June-10-2020
Last Update:
Dec-15-2024
FDA-Approved Indications
NYVEPRIA (pegfilgrastim-apgf) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Nyvepria® (Pfizer) (November-2020)
Inter Partes Review Proceedings
U.S. Patent Litigations
